The biotech sector appears to be in the midst of a classic equity bubble, with hype, instead of fundamentals, driving stock prices. To be specific, there are a number of mid-cap biotechs with no revenue to speak of, and deficits reaching into the billions, that have recently attained multi-billion dollar market caps based solely on the "potential" of their flagship drug candidates. And when these drugs do finally reach the market, fundamentals kick into overdrive, acting like a black hole on share prices. Arena Pharmaceuticals (NASDAQ:ARNA), Avanir Pharmaceuticals (NASDAQ:AVNR) Dendreon (NASDAQ:DNDN), Horizon Pharma (NASDAQ:HZNP) are just a few examples of this widespread phenomenon in the biotech sector.
With all the hype surrounding ...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|